ChemoCentryx slides on diabetic nephropathy data

ChemoCentryx Inc. (NASDAQ:CCXI) fell $2.01 (24%) to $6.25 on Tuesday after reporting interim data from 332 evaluable patients in a Phase II trial evaluating CCX140 to treat diabetic nephropathy. In the trial, once-daily oral CCX140 plus standard of care (SOC) reduced proteinuria from baseline to week two by 12% at the 5 mg dose and by 8% at the 10 mg dose vs. an increase of 1% for placebo plus SOC (p<0.05 for low-dose CCX140 compared to placebo). SOC consisted of stable doses of an angiotensin-converting enzyme (ACE) or angiotensin-receptor blocker (ARB). ...